In the Chinese phase III, DAWNA-2 study presented by Xu el al, the addition of the CDK 4/6 inhibitor #Dalbiciclib to 1st line Aromatase inhibitor significantly prolonged progression free survival in HR+/HER2- metastatic #breast_cancer. The median PFS was 30.6 vs 18.2 months in the dalpiciclib versus the placebo group respectively, (HR 0.51; P <0.0001). By these results, Dalpiciclib becomes the 4th CDK4/6 inhibitor that improved PFS in the first line setting. Of note, dalpiciclib had previously shown similar PFS improvement in the second line setting when added to Fulvestrant in the DAWNA-1 study.